PCI has divulged that it is making significant investment at its site near Dublin, Ireland to strengthen its position globally and to ensure pharmaceutical supply is uninterrupted for its customers after Brexit.
PCI has divulged that it is making significant investment at its site near Dublin, Ireland to strengthen its position globally and to ensure pharmaceutical supply is uninterrupted for its customers after Brexit, which is set to happen on Oct. 31, 2019.
The investment will be used to build a dedicated clinical facility that will, once completed, provide more than 75,000 sq. ft. of space to the business, which will be used as a center for primary and secondary packaging, storage, logistics, and distribution. Forming a part of the company’s overall global expansion plans, the new Irish facility will increase capabilities and capacity for the clinical services business.
“Our growth strategy is focused on the continued expansion of our global network to support growing demand from our customers and providing a solution for Brexit through ongoing investment in capacity, capability expansion and talent,” said PCI chief executive officer Salim Haffar in an Aug. 27, 2019 press release. “We are very pleased with our team’s progress in expanding our global footprint as we partner with our customers in the shared goal of improving patients’ lives.”
Source: PCI
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.